Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CGRP antagonists

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

- PMLiVE

Gilead settles patent dispute with Teva over Viread generic

Launch of generic HIV drug held back until December 2017

Teva facing $2bn liability for at-risk generic Protonix launch

Potential litigation costs from Pfizer are triple the generics firm's original estimates

- PMLiVE

Teva wins challenge to BMS’ Baraclude patent in US

US court says hepatitis B treatment’s patent is invalid

- PMLiVE

Allergan boosts migraine standing with $1bn acquisition

Acquires Californian neurology specialist MAP Pharmaceuticals

- PMLiVE

Teva suffers setback as Nuvigil fails late-stage trial

Disappointing results in treating bipolar disorder but drug development continues

- PMLiVE

Teva expands presence in South Korea with Handok deal

Will supply products for distribution in market worth $14bn

- PMLiVE

Teva plans revamp as 2013 revenues expected to fall short

Expects increased competition for biggest-selling drug Copaxone

- PMLiVE

Teva promotes Allan Oberman to take over from William Marth

Executive leadership changes also see Jill DeSimone join

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

Europe set to approve first Glivec generic

CHMP backs Teva version of Novartis' blockbuster cancer drug

Teva pulls generic version of antidepressant Wellbutrin XL in US

FDA says copy is not equivalent to branded drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links